口服托法西提尼布用于具有耐火性的泛型道林氏病:一个病例报告
Luan Yang1, Ming Jing1, Zhenqiang Ruan1
1Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital, Jinan, Shandong, P. R. China.
The Journal of dermatological treatment
|June 18, 2025
概括
托法西替尼有效地减少了一般化道林氏病 (DDD) 的严重. 这种Janus激酶 (JAK) 抑制剂为DDD患者提供了有前途的治疗方法,这些患者经历了耐火性.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 泛性道林氏病 (DDD) 是一种罕见的遗传性疾病,其特征是渐进的网状超色素化.
- 耐火性是DDD的衰弱症状,显著影响患者的生活质量.
- 传统疗法经常为DDD相关的提供有限的缓解.
研究的目的:
- 评估tofacitinib的疗效和安全性,一个Janus激酶 (JAK) 抑制剂,对于具有严重的泛型DDD.
- 为了比较tofacitinib的好处和缺点与已建立的DDD治疗方法.
主要方法:
- 一个61岁男性的案例研究,他有20年的DDD和难治性的病史.
- 通过皮肤镜检查和组织病理学来确认诊断.
- 治疗始于口服阿西特雷丁和普雷迪松,其次是托法西提尼布单一治疗 (每天两次5毫克).
主要成果:
- 阿西特雷丁使恶化;然而,托法西替尼显著改善了的得分 (NRS在1个月内从9到56,在4个月内稳定在2-3).
- 在没有症状复发的情况下观察到损伤变黑.
- 在tofacitinib治疗期间没有报告任何不良事件.
结论:
- 托法西替尼 (tofacitinib) 显示出作为一般性DDD与耐火性的安全有效治疗的巨大潜力.
- 这种JAK抑制剂为那些对现有治疗无反应的患者提供了一种新的治疗途径.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
Inflammatory Bowel Disease IV: Clinical Manifestations
Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...


